FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy

(June 7, 2021) – Medtronic announced receipt of U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System for Deep Brain Stimulation (DBS) therapy. SenSight™ allows physicians to deliver precise, patient-specific DBS therapy. Click here to learn more about Medtronic and SenSight™.

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.